Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 9, 2019

View Archived Issues

Brain kinase induces spinal cord regeneration

Microfluidics method broadens human iPSC potential

Brain regulatory T cells potentiate neurological recovery

Oppilan Pharma initiates phase I study of OPL-002

Regulus announces clinical candidate nomination for RGLS-5579 for GBM

Oncolys BioPharma initiates phase II study of Telomelysin in combination with pembrolizumab

Patient enrollment begins in phase II study of CPI-613 in Burkitt lymphoma/leukemia

Kymab initiates phase II study of KY-1005 in atopic dermatitis

Patient recruitment ongoing in first-in-human study of IBI-101

Georgia State University describes new carbon monoxide-releasing molecules

Tarlige tablets receive approval in Japan for the treatment of peripheral neuropathic pain

Inovio initiates first-in-human study of DNA-encoded monoclonal antibody for Zika

The General Hospital Corp. patents new CYP1 inhibitors

Combining novel MCL-1 inhibitor with MEK inhibitors as promising new strategy in KRAS-mutant NSCLC

Genentech and Roche disclose IRAK-4 inhibitors

Medshine Discovery presents TLR8 agonists

CX-23, an NQO1-selective activated prodrug of triptolide, shows promise in preclinical models of HCC

Chinese researchers identify compounds for estrogen receptor-mediated diseases

Spero and Everest Medicines sign license and option agreements for SPR-206 and SPR-741 in Asia

Japan first to approve Evenity for osteoporosis

MediciNova opens enrollment in phase I/II study of MN-166 with temozolomide in GBM

Demser approved in Japan to improve catecholamine excess secretion in patients with pheochromocytoma

Japanese approval for Braftovi and Mektovi for unresectable melanoma with BRAF mutation

Wockhardt presents first clinical data for WCK-5222 in patients with renal impairment

IAVI initiates phase I trial of BG505 SOSIP.664 gp140 in HIV-uninfected subjects

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...